Volver a Agenda
Session 18: FDA Warning Letters
Session Chair(s)
Mark Vieder, MBA, RPH
Vice President, Drug Safety and Pharmacovigilance
Biorasi, LLC, United States
A review of recent findings from several FDA Post-Marketing Adverse Drug Experience inspections will be discussed using Warning Letters to identify observations.
¿Tiene una cuenta?